Pioglitazone News and Research

RSS

Diabetes drug pioglitazone shows potential against multiple sclerosis

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.

26 May 2009

Psoriasis increases risk for developing diabetes and hypertension in women

Women with psoriasis appear to have an increased risk for developing diabetes and hypertension (high blood pressure), according to a report in the April issue of Archives of Dermatology.

21 Apr 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

$Thiazolidinediones doubles risk of fractures in women$

Thiazolidinediones doubles risk of fractures in women

New findings out of Wake Forest University School of Medicine and the University of East Anglia show that long-term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes.

10 Dec 2008

New evidence shows that the heart beats to its own drummer

They've uncovered some of the molecular circuitry within the cardiovascular system itself that controls the daily rise and fall of blood pressure and heart rate. The findings might also explain why commonly used diabetes drugs come with cardiovascular benefits, according to the researchers.

3 Dec 2008

Risks associated with diabetes drug rosiglitazone may be higher than those with pioglitazone

Older adults who take the diabetes medication rosiglitazone appear to have a higher risk of death and heart failure than those taking the related medication pioglitazone, according to a report in the November 24 issue of Archives of Internal Medicine.

24 Nov 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

A class of oral drugs used to treat type 2 diabetes may significantly increase the risk of serious cardiovascular events, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

28 Aug 2008

Thiazolidinediones may slow bone formation and speed bone loss

A widely used class of diabetes medications appears to be associated with an increased risk for fractures, according to a report in the April 28 issue of Archives of Internal Medicine.

28 Apr 2008

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline.

1 Apr 2008

New understanding of the link between heart disease and belly fat

By now, everyone knows that overweight people have a higher risk of heart attacks, strokes and other problems that arise from clogged, hardened arteries. And people who carry their extra weight around their waist - giving them a "beer belly" or an "apple" shape - have the highest risk of all.

22 Jan 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Older patients treated with the diabetes medications known as thiazolidinediones (which include rosiglitazone) had a significantly increased risk of heart attack, congestive heart failure and death, compared with the use of other hypoglycemic drugs, according to a study in the December 12 issue of JAMA.

13 Dec 2007

Anti-diabetic drug pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease

A new study confirms that chronic kidney disease (CKD) increases the already-high risk of serious cardiovascular events in diabetic patients with damage to the large blood vessels and suggests that treatment with the anti-diabetic drug pioglitazone may help to lower this risk, reports the January Journal of the American Society of Nephrology.

13 Dec 2007

Study finds Avandia may increase risk of heart failure

A popular class of drugs for treating type 2 diabetes is under scrutiny again. A new Canadian study released by the Institute for Clinical Evaluative Sciences (ICES) finds that drugs such as Avandia increase the risk of heart failure, heart attacks and death.

13 Dec 2007

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.

19 Nov 2007

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

Patients with type 2 diabetes* or prediabetes* are more likely to develop congestive heart failure (CHF) when given rosiglitazone or pioglitazone, as compared with controls. However these drugs did not increase the risk of cardiovascular death (CVD) for these patients.

1 Oct 2007

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

Results presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes.

20 Sep 2007

Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events

A meta-analysis of previous research suggests that use of pioglitazone, a glycemic control medication for patients with type 2 diabetes, significantly reduces the risk of heart attack, stroke and death, but increases the risk for serious heart failure, according to an article in the September 12 issue of JAMA: The Journal of the American Medical Association.

12 Sep 2007

Pioglitazone News and Research

Diabetes drug pioglitazone shows potential against multiple sclerosis

Psoriasis increases risk for developing diabetes and hypertension in women

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Thiazolidinediones doubles risk of fractures in women

New evidence shows that the heart beats to its own drummer

Risks associated with diabetes drug rosiglitazone may be higher than those with pioglitazone

Advances in the management of diabetes mellitus

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

Thiazolidinediones may slow bone formation and speed bone loss

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

New understanding of the link between heart disease and belly fat

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Anti-diabetic drug pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease

Study finds Avandia may increase risk of heart failure

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News